Buying interest flowed into diagnostic and pharmaceutical stocks following reports of suspected infectious disease cases overseas. However, as it has not been confirmed whether a pathogen was released, expectations surrounding the issue should be distinguished from the companies' actual business exposure. Investors who have identified potential investments by examining the relevant companies' products and revenue bases can also assess how much capital they may need.


For investors considering opportunities in the diagnostics and pharmaceutical sectors but short on buying power because their funds are tied up in existing holdings, a stock-backed loan using a brokerage account may be an option. Depending on the account and eligible stocks, investors can use up to four times their equity, including their own capital, to add to positions in stocks they are watching or expand their investment options. However, stocks sensitive to current issues may be highly volatile or subject to purchase restrictions, so investors should check eligibility and collateral requirements. Comparing the applicable interest rate, additional fees, and collateral maintenance requirements, and determining the amount to borrow within their repayment capacity, can help them develop a more specific investment plan based on their analysis of the companies.

Diagnostic and Pharma Stocks Rise on Infectious Disease Concerns... Seize Opportunities with Up to 4x Investment Capital View original image

Meanwhile, interest in stock-backed loans is growing steadily. Investors looking to avoid missing investment opportunities are turning to stock-backed loans, which allow them to use more funds to buy stocks.


Another advantage of stock-backed loans is that investors using margin or credit financing can switch over easily, without providing additional collateral or selling stocks, if a sharp decline in share prices puts them at risk of forced liquidation, and then wait for a rebound.


◆ All New Stock Loan launches a product with an industry-low interest rate in the 5% range per year!

All New Stock Loan has launched a securities-linked credit product with an industry-low interest rate in the 5% range per year, so investors can use a stock-backed loan without undue burden. The product can be used to buy stocks and refinance margin or credit financing from securities firms, and offers up to four times the user's equity, including their own capital, regardless of credit rating. Investors who use the alternative trading system (NXT) can also use the service.


Investors who want to learn more about All New Stock Loan can contact its customer service center at 1599-8666 to speak with a professional adviser at any time, regardless of whether they qualify for a loan.


○ Product launched with an industry-low interest rate in the 5% range per year!

○ ETF trading available

○ Use up to four times your equity for stock investments! (Including your own capital)

○ Same-day refinancing of securities credit or margin financing available!

○ Trading through the alternative trading system (NXT) available

○ OK even for stocks that were difficult to buy using credit from your existing securities firm or a stock-backed loan!

* All New Stock Loan Customer Service Center: 1599-8666

Link: https://allnewstockloan.co.kr


Samsung Electronics Preferred Shares, Daeduck Electronics, Hanwha Aerospace, Kukje Pharma, LG Innotek



※ This content does not reflect the editorial direction of The Asia Business Daily, and the information provider is solely responsible for it.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing